Top Page
Pangea Natural Food, Inc.
(PNGA)
Pangea Natural Food, Inc. (PNGA) vs. iShares MSCI Canada ETF (EWC)
Pangea Natural Food, Inc. Business Overview & Revenue Model
Pangea Natural Food, Inc. Financial Statement Overview
| Breakdown | ||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 4.18K | 12.20K | 285.59K | 698.26K | 68.50K | Gross Profit |
| -106.26K | 6.91K | -32.79K | 40.97K | -67.25K | EBIT |
| -770.53K | -920.71K | -1.64M | -663.52K | -173.20K | EBITDA |
| -964.75K | -917.21K | -1.64M | -898.44K | -172.28K | Net Income Common Stockholders |
| -1.02M | -1.03M | -1.66M | -1.61M | -173.19K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 211.28K | 140.09K | 51.64K | 75.95K | 807.57K | Total Assets |
| 288.30K | 182.29K | 191.72K | 620.34K | 1.34M | Total Debt |
| 21.22K | 17.83K | 0.00 | 0.00 | 0.00 | Net Debt |
| -190.05K | -122.27K | -51.64K | -75.95K | -807.57K | Total Liabilities |
| 782.08K | 732.74K | 330.00K | 408.57K | 116.82K | Stockholders Equity |
| -493.78K | -550.45K | -138.28K | 211.76K | 1.23M |
| Cash Flow | Free Cash Flow | |||
| -434.48K | -439.41K | -980.68K | -725.80K | -590.75K | Operating Cash Flow |
| -434.48K | -439.41K | -980.68K | -718.60K | -529.76K | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | -7.20K | -60.98K | Financing Cash Flow |
| 576.21K | 527.86K | 956.37K | -1.32K | 1.40M |
Pangea Natural Food, Inc. Technical Analysis
Pangea Natural Food, Inc. Peers Comparison
Pangea Natural Food, Inc. Corporate Events
Pangea Natural Foods Inc. announced a change in its auditing firm, replacing MNP LLP with SHIM & Associates LLP, effective October 31, 2024. This change was approved by the company’s board of directors following a recommendation from the audit committee. The company aims to correct an error in the management information circular that incorrectly stated MNP would be reappointed. Instead, shareholders will vote to appoint SHIM as the auditors at the upcoming annual general meeting. This move is part of Pangea’s ongoing efforts to maintain transparency and accuracy in its financial reporting, which is crucial for its operations and stakeholder trust.
Spark’s Take on TSE:PNGA Stock
According to Spark, TipRanks’ AI Analyst, TSE:PNGA is a Underperform.
Pangea Natural Food, Inc. has substantial financial challenges, including negative margins and cash flows, which heavily impact its overall stock score. While technical indicators show some upward momentum, the stock is overbought, adding risk. The valuation remains unattractive due to negative earnings. Recent corporate events, such as acquisitions and financing, could provide future opportunities but do not counterbalance the current financial distress.
To see Spark’s full report on TSE:PNGA stock, click here.
Pangea Natural Foods Inc. has announced a non-brokered private placement to raise up to $2.9 million through the issuance of 11.6 million special warrants. Each warrant will convert into a unit comprising one common share and one share purchase warrant, with the proceeds intended for working capital. The offering is subject to regulatory approvals and is expected to close by May 9, 2025, potentially enhancing Pangea’s financial flexibility and operational capacity.
Spark’s Take on TSE:PNGA Stock
According to Spark, TipRanks’ AI Analyst, TSE:PNGA is a Neutral.
Pangea Natural Food, Inc.’s overall stock score reflects significant financial distress and lack of profitability, despite potential upside from strategic acquisitions. While technical indicators show short-term momentum, the negative valuation metrics and ongoing financial challenges weigh heavily on the overall score.
To see Spark’s full report on TSE:PNGA stock, click here.
Pangea Natural Foods Inc. has acquired Amino Innovations Corp., a company specializing in innovative peptide therapies for health and wellness, through the issuance of 12 million common shares. This acquisition aims to enhance Pangea’s product offerings and market position by integrating Amino’s expertise in peptide formulations, potentially making it the world’s first needleless peptide company. The transaction includes performance-based conditions for the release of shares and a finder’s fee paid in Pangea shares.
Spark’s Take on TSE:PNGA Stock
According to Spark, TipRanks’ AI Analyst, TSE:PNGA is a Neutral.
Pangea Natural Food, Inc.’s overall stock score reflects significant financial distress and lack of profitability, despite some potential upside from recent corporate actions. The technical analysis provides a neutral outlook, while the valuation remains unattractive due to negative earnings. The company’s strategic initiatives could drive future growth, but operational and financial challenges remain substantial.
To see Spark’s full report on TSE:PNGA stock, click here.
Pangea Natural Foods Inc. has announced a definitive agreement to acquire Amino Innovations Corp., a company specializing in innovative peptide therapies for health and wellness. This acquisition aligns with Pangea’s strategy to expand its product offerings in the health and longevity sector, potentially enhancing its market position by integrating Amino’s needleless peptide technology and product lines.
Pangea Natural Foods Inc. announced a consolidation of its common shares on a six-to-one basis, reducing the number of shares from approximately 86 million to 14 million. This move, approved by the board, will commence trading on a post-consolidation basis on February 18, 2025, and aims to streamline the company’s share structure while maintaining the same company name and stock symbol.
Pangea Natural Foods Inc. has announced a non-binding letter of intent to acquire Amino Innovations Corp, a company specializing in innovative peptide therapies for health and wellness. The proposed transaction involves a share exchange whereby Pangea will issue 12,000,000 common shares to acquire all of Amino’s shares, resulting in Amino shareholders owning approximately 45.5% of Pangea. This acquisition aligns with Pangea’s strategy to expand its product portfolio into the growing sector of peptide-based health solutions, potentially enhancing its market position and offering significant opportunities for stakeholders.